2011
DOI: 10.1038/bmt.2011.146
|View full text |Cite
|
Sign up to set email alerts
|

Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
25
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(26 citation statements)
references
References 185 publications
1
25
0
Order By: Relevance
“…2). Consistent with our results, interaction between AMB and P-gp has been suggested by other pieces of evidence from studies on animal intestines (13,14,25). In a study by Ishizaki and colleagues, the oral bioavailability of cyclosporine was decreased after coadministration of AMB in Wistar rats, presumably due to the increased P-gp expression induced by AMB at the duodenum (14).…”
Section: Discussionsupporting
confidence: 80%
“…2). Consistent with our results, interaction between AMB and P-gp has been suggested by other pieces of evidence from studies on animal intestines (13,14,25). In a study by Ishizaki and colleagues, the oral bioavailability of cyclosporine was decreased after coadministration of AMB in Wistar rats, presumably due to the increased P-gp expression induced by AMB at the duodenum (14).…”
Section: Discussionsupporting
confidence: 80%
“…have resulted in a rise in life threatening co-conditions like invasive fungal infections (IFIs). Several triazole anti-fungal agents such as fluconazole, ketonazole, itraconazole, voriconazole and posaconazole are used for treatment to improve the therapeutic efficacy [1]. Voriconazole (Vrc), a structural derivative of fluconazole, is a second-generation triazole with broad-spectrum antifungal activity.…”
Section: Introductionmentioning
confidence: 99%
“…Polymorphism may ultimately affect drug effi cacy: CYP2C19 variation leads to a fi vefold variation in voriconazole levels between individuals. In the future, routine provision of pharmacogenomic data for new drugs together with accumulating knowledge about established agents will challenge physicians to assimilate and apply that information in drug prescribing (Ashbee and Gilleece 2011 ).…”
Section: Personalized Management Of Fungal Infectionsmentioning
confidence: 99%